Sepio Capital LP Acquires 587,854 Shares of Abbott Laboratories $ABT

Sepio Capital LP raised its holdings in Abbott Laboratories (NYSE:ABT) by 296.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 786,102 shares of the healthcare product maker’s stock after buying an additional 587,854 shares during the period. Abbott Laboratories makes up approximately 3.1% of Sepio Capital LP’s portfolio, making the stock its 7th largest position. Sepio Capital LP’s holdings in Abbott Laboratories were worth $77,691,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ABT. Manning & Napier Advisors LLC acquired a new stake in shares of Abbott Laboratories in the second quarter valued at $31,000. Summit Securities Group LLC boosted its holdings in Abbott Laboratories by 41.3% in the second quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker’s stock valued at $37,000 after purchasing an additional 118 shares during the period. Addison Advisors LLC acquired a new position in Abbott Laboratories during the 2nd quarter worth $40,000. E Fund Management Hong Kong Co. Ltd. grew its stake in Abbott Laboratories by 221.6% during the 2nd quarter. E Fund Management Hong Kong Co. Ltd. now owns 476 shares of the healthcare product maker’s stock worth $43,000 after purchasing an additional 328 shares in the last quarter. Finally, Allied Private Wealth LLC purchased a new stake in Abbott Laboratories during the 2nd quarter worth about $45,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported third-quarter adjusted EPS of $1.42, in line with the main consensus estimate, and revenue of $13.01 billion, slightly above the $12.99 billion estimate. Reported sales rose 14.5% year over year, while comparable sales increased 7%. Abbott third-quarter results
• Positive Sentiment: Abbott reaffirmed its full-year adjusted EPS guidance, and analysts continue to see upside. Wells Fargo raised its price target to $119, while Robert W. Baird raised its target to $123. Citigroup, RBC, JPMorgan, TD Cowen and BTIG lowered targets but retained bullish ratings, including “buy,” “outperform” or “overweight.”
• Positive Sentiment: The company received European approval for its Cologuard Plus colorectal-cancer screening test, expanding the potential market for its diagnostics portfolio. Abbott Cologuard Plus European approval
• Neutral Sentiment: Abbott plans a tax-free separation of its approximately $8.5 billion Nutrition business into an independent, publicly traded company by the end of 2027. Management says the move could give both businesses more focused investment strategies, but investors face execution, allocation and valuation uncertainty during the transition. Abbott Nutrition separation announcement
• Negative Sentiment: Abbott reduced its 2026 sales-growth outlook, citing pressure from diabetes-related pricing and weakness in parts of its electrophysiology and medical-device businesses. This softer outlook overshadowed the quarterly revenue performance and led several analysts to trim price targets. Abbott lowers 2026 sales forecast
• Negative Sentiment: India’s food regulator issued a notice involving infant-formula claims related to Nestlé India and Abbott, creating a limited regulatory overhang for Abbott’s Nutrition operations. India infant-formula regulatory notice

Analysts Set New Price Targets

A number of research firms have issued reports on ABT. Robert W. Baird increased their price target on Abbott Laboratories from $121.00 to $123.00 and gave the company an “outperform” rating in a research report on Thursday. Weiss Ratings raised Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 18th. TD Cowen lowered their price objective on Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating for the company in a research report on Thursday. UBS Group cut their target price on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Finally, Citigroup reduced their target price on shares of Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating on the stock in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.32.

Abbott Laboratories Stock Up 2.1%

Shares of NYSE ABT opened at $102.64 on Friday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $132.02. The firm’s 50-day simple moving average is $105.30 and its 200 day simple moving average is $98.28. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The company has a market cap of $177.61 billion, a price-to-earnings ratio of 33.22, a price-to-earnings-growth ratio of 1.86 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. The business had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. During the same period in the previous year, the firm posted $1.30 earnings per share. Abbott Laboratories’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s dividend payout ratio is 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.